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To the Editor: In a recent issue of Kidney International,
Khosla et al.1 have demonstrated that hyperuicemia per
se induces endothelial dysfunction by in vitro and in vivo
studies, in which hyperuricemia was induced in male
Sprague–Dawley rats with an uricase inhibitor, oxonic acid.
However, some issues need to be clarified before this model is
applied to the clinical practice. First, hyperuricemia in
modern humans is frequently associated with high purine
metabolism, accompanied by increased activity of xanthine
oxidoreductase with increased production of reactive oxygen
species,2 rather than a pure accumulation of uric acid due to
impairment of its further metabolism or excretion. Con-
sidering that reactive oxygen species are strongly associated
with endothelial dysfunction, dual blockade of reactive
oxygen species and uric acid production in purine meta-
bolism pathway by xanthine oxidoreductase inhibitors (e.g.
allopurinol) or low-purine diet might be more effective than
uricosuric agents (e.g. benzbromazone). Further head-to-
head in vivo studies with control of serum uric acid level may
help to clarify this issue. Second, hyperuricemia is frequently
clustered with metabolic syndrome, diabetes mellitus, and
essential hypertension in humans.3 The additional benefit of
lowering serum uric acid level on the base of well-controlled
metabolic syndrome, diabetes mellitus, and essential hyper-
tension should be further evaluated. Third, the potential
life-threatening adverse effects and clinical benefits (e.g. reduc-
tion of cardiovascular morbidity or mortality) of xanthine
oxidoreductase inhibitors for those asymptomatic hyper-
uricemia patients should be wholesomely evaluated because
the incidence of allopurinol-induced hypersensitivity syndrome
(especially exfoliative dermatitis, hepatitis, nephritis, or pneum-
onitis), Stevens–Johnson syndrome, and toxic epidermal
necrolysis might significantly increase after its widespread use.
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